Do not miss the upcoming DIABESITY CME to be held in Maribor (Slovenia) on September 16-17, 2022.
Click here to learn more.


DIABESITY, an ERA Working Group focusing on the Nephrological Impact in relation to DIABETES and OBESITY

DIABESITY consists in a Working Group of European investigators aiming at creating and disseminating knowledge on the nephrological impact of Diabetes and Obesity. European research in this field is already of very high quality. However, the magnitude of the problem requires strong and multinational collaborations between teams specialized in different aspects of diabetes and obesity (basic and clinical). This can help the interchange of knowledge and skills between established scientists in the field. By combining various local expertises, EU collaboration could additionally benefit translational and cross-functional research on renal consequences of Diabesity. Finally, this collaborative effort should transfer to a better communication between research, patients and society.


Mads Hornum (Denmark) – Chair
Maru Navarro Díaz (Spain) – Vice-Chair
Sebastjan Bevc (Slovenia)
Trond G. Jenssen (Norway)
Khaled Khazim (Israel)
Ivo Laranjinha (Portugal)
Enrique Morales (Spain)
Esteban Porrini (Spain)
Matias Trillini (Italy)
Francesco Trevisani (Italy)


Being a ordinary member of the DIABESITY y Working Group means being part of a network which facilitates exchanges of ideas on basic science research and new treatment protocols.

Becoming an ordinary member of the DIABESITY Working Group is FREE OF CHARGE. Ordinary members must be ERA members and be persons with a proven interest in the research area covered by the WG. Exceptions are possible only for non-nephrologists.

By joining the DIABESITY Working Group you will receive constant updates on the Working Group initiatives be included in the Directory of DIABESITY Working Groups’ ordinary members and start networking with colleagues from all over the world.

Click here to join.

The ordinary membership application is subject to validation. Please allow some time for a quick administrative check before applying multiple times.


The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease
Kidney International Reports, June 2021

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Nephrology Dialysis and Transplantation, February 2019

Beta Cell Functional Adaptation and Dysfunction in Insulin Resistance and the Role of Chronic Kidney Disease
Nephron, January 2019
Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney? Nephron, January 11, 2019

Escasany E. Izquierdo-Lahuerta A. Medina-Gomez G. Underlying Mechanisms of Renal Lipotoxicity in Obesity, Nephron, January 9, 2019

Correia-Costa L., Azevedo A., Caldas Afonso A. Childhood Obesity and Impact on the Kidney, Nephron, October 25, 2018

Pérez-Morales R.E., del Pino M.D Valdivielso J.M. Ortiz A.Mora-Fernández C. Navarro-González J.F, Inflammation in Diabetic Kidney Disease, Nephron, October 2018

Porrini E, Warnock DG. Evaluation of Renal Function and Renal Risk in the Twenty-First Century. Nephron. 2017;136(4):261-262. doi: 10.1159/000471757.

Luis-Lima S, Porrini E. An Overview of Errors and Flaws of Estimated GFR versus True GFR in Patients with Diabetes Mellitus. Nephron. 2017;136(4):287-291. doi: 10.1159/000453531.

Praga M, Morales E. The Fatty Kidney: Obesity and Renal Disease. Nephron. 2017; 136(4): 273-276.  doi: 10.1159/000447674.

Trevisan R, Dodesini AR.The Hyperfiltering Kidney in Diabetes. Nephron. 2017;136(4):277-280.

Cortinovis M, Perico N, Remuzzi G. Should We Still Believe in Randomized Controlled Trials in Nephrology? Nephron. 2017;136(4):281-286.

Castillo-Rodriguez E1, Fernandez-Prado R, Martin-Cleary C, Pizarro-Sánchez MS, Sanchez-Niño MD, Sanz AB, Fernandez-Fernandez B, Ortiz A.
Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. Nephron. 2017;136(4):263-267.

Hojs R, Ekart R, Bevc S, Hojs N. Markers of Inflammation and Oxidative Stress in the Development and Progression of Renal Disease in Diabetic Patients. Nephron.  2016;133(3):159-62.

Hornum M, Feldt-Rasmussen B. Drug Dosing and Estimated Renal Function – Any Step Forward from Effersoe? Nephron. 2017;136(4):268-272.

Hornum M, Feldt-Rasmussen B. Glomerular Filtration Rate Estimation in Renal and Non-Renal Solid Organ Transplantation. Nephron. 2017;136(4):298-301.  Nephron. 2017;136(4):292-297. doi: 10.1159/000455197.

Warnock DG, Delanaye P, Glassock RJ. Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria. Nephron. 2017;136(4):292-297. doi: 10.1159/000455197.

D’Agati VD, Chagnac A, de Vries AP, Levi M, Porrini E, Herman-Edelstein M, Praga M. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.Nat Rev Nephrol. 2016 Aug;12(8):453-71. doi: 10.1038/nrneph

Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(5):382-91.

de Vries APJ, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, D’Agati VD, Lamb HJ, Pongrac Barlovic D, Hojs R, Abbate M, Rodriquez R, Mogensen CE, Porrini E;
ERA-EDTA Working Group Diabesity. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol.
“There is enough growing insight that ectopic lipid—the accumulation of lipid in non-adipose tissue—is associated with structural and functional changes of mesangial cells, podocytes, and proximal tubular cells to propose the development of obesity related glomerulopathy as a maladapted response to hyperfiltration and albuminuria. In this Review, we discuss the emerging role of ectopic lipid (the accumulation of lipid in non-adipose tissue) from metabolically unhealthy obesity as a novel pathway of obesity-related renal disease.”

Porrini E, Ruggenenti P, Mogensen C-E, Pongrac Barlovic D, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries APJ, for the ERA-EDTA Working Group Diabesity.
A Role for Non-Proteinuric Pathways in loss of Renal Function in patients with Type 2 DIABETES? Lancet Diabetes Endocrinol, 2015, in press.
“In this personal view we analyze a novel phenotype of renal function decline in type 2 diabetes. Largely on the basis of data in type 1 diabetes, the natural history of diabetic renal disease has been categorized in a sequence of stages: normoalbuminuria, microalbuminuria and macroalbuminuria. Progressive decline of glomerular filtration rate was thought to parallel the onset of macroalbuminuria (overt nephropathy), whereas glomerular hyperfiltration was considered a hallmark of earlier stages. Recent studies clearly demonstrated that albuminuria is a continuum and that the GFR may start to decline before progression to overt nephropathy. In addition to proteinuria, other risk factors may sustain GFR deterioration including female gender, obesity, dyslipidemia (in particular hypertriglyceridemia), hypertension and glomerular hyperfiltration. This may explain why patients with type 2 diabetes can have renal insufficiency even before the onset of overt nephropathy.”


ENBiBA: European Nephrectomy Bio-Bank

The epidemic of obesity and type 2 diabetes (T2DM) may portend severe consequences in nephrology. Obesity and diabetes represent a continuum of metabolic alterations which can greatly increase the chance of renal disease. Common markers of renal damage in diabetes and obesity include i.e. insulin resistance, hypertension, prediabetic alterations in glucose metabolism, insulin resistance, hyperuricaemia, dyslipidemia and lipotoxicity, chronic sub-clinical inflammation, unhealthy obesity, glomerular hyperfiltration and albuminuria. Renal histological changes associated with obesity (metabolically healthy or unhealthy) and early diabetic nephropathy are mostly unknown. The major limitation for studying early histological changes of obesity and diabetes is that renal biopsies are not performed due to ethical concerns. To solve this limitation, we propose the creation of a bio-bank of unaffected renal tissue of pieces of nephrectomy, to study the following points: (a) the histological pattern of renal damage in the whole spectrum of obesity (not only extreme obesity); (b) histological changes in healthy and unhealthy obesity with the same degree of BMI; (c) similarities in renal histology between early diabetes and metabolically unhealthy obesity; (d) the impact of metabolic factors on obesity-related renal damage; (e) possible pathogenetic pathways i.e. lipotoxicity or sub-clinical inflammation in obesity driven renal disease; (f) the prevalence of markers of chronic disease i.e. glomerulsclerosis, tubular and interstitial fibrosis in patients with obesity and early diabetes. This also will give the possibility of analyzing pathogenetic pathways involved in renal damage associated with these diseases.

Today, 15 centres from  7 countries are participating in the project: Portugal (3), Spain, Spain (8), Italy (1), Slovenia (1), Denmark (1) and Israel (1). More than 500 cases have been included, 100 with type 2 diabetes. We are currently preparing the first manuscript with the analysis of renal histology in patients with diabetes, normoalbuminuria, microalbuminuria or proteinuria and diverse degrees of renal function.

If you are interested in the ENBiBA project, send an e-mail to: 


Renal disease in obesity-overweight-metabolic syndrome and diabetes project was selected to be one of the projects to be supported by the ERA through the Long Term Fellowship Programme.


Diabesity CME Course 2022

The course will be held on September 16-17, 2022 in Maribor (Slovenia)

Venue: Faculty of Medicine, University of Maribor

Provisional programme available here.

Registration is reserved to ERA members and is free of charge.

For more info and registrations please contact the Local Organiser: Prof. Sebastjan Bevc (

An application has been made to the UEMS EACCME® for CME accreditation of this event.


Overweight, obesity and extreme obesity: links with renal disease
ERA WG e-seminar series #19 – organised by DIABESITY
Click here to watch the webcast of the event

Post Transplant Diabetes 2021
ERA WG e-seminar series #15 – organised by DIABESITY
Click here to watch the webcast of the event

GLP-1 in kidney transplantation-is it feasible? Indications, clinical challenges, side effects and outcome – March 11, 2021
ERA WG e-seminar series #4 – organised by DIABESITY
Click here to watch the webcast of the event

Treatment of diabetes, obesity and assessment of end organ damage (kidney and liver/intestine) – June 18-19, 2021
This symposium, organised by the Danish Diabetes Academy and DIABESITY, is designed for basic and clinical researchers, Ph.D.-students, medical students, industry trial planners and directors, industry technical staff working within any field of diabetes, including both clinical, basic and translational research/work and/or interdisciplinary research/work within fields related to diabetes.
Click here to watch the webcast of the event


Treatment of diabetes, obesity and assessment of end organ damage (kidney and liver/intestine)

This symposium, organised by the Danish Diabetes Academy and DIABESITY was intended for basic and clinical researchers, Ph.D.-students, medical students, industry trial planners and directors, industry technical staff working within any field of diabetes, including both clinical, basic and translational research/work and/or interdisciplinary research/work within fields related to diabetes.

The aim was to facilitate a high-quality symposium in the assessment and treatment of end organ damage in kidney and metabolic disease by providing new markers of interest, ultrasound and scanners and laboratory equipments of interest in kidney, liver and diabetes management and assessment.

Furthermore, to gain insight in gut peptide biology and clinical implications for diabetic and obese patients.

The meeting was held on June 18-19, 2021 in Copenhagen (Denmark).

Click here to view the webcast